Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,281 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: HIV Infections, Substance Use, Adherence, Medication, Adherence, Treatment
Interventions: Descovy or Truvada, ID-Cap System, Beiwe; Drug · Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prevention of Chikungunya Virus Infection
Interventions: mRNA-1944, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV/AIDS
Interventions: Infographic Intervention, Paper-based HIV self-testing information; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years to 34 Years · Male only
Enrollment: 322 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Post Operative Surgical Site Infection
Interventions: Treatment group, Control group; Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • Redwood City, California + 35 more

Conditions: Marburg Hemorrhagic Fever
Interventions: AVI-6003, Placebo; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Cypress, California

Conditions: Human Immunodeficiency Virus, Stigma, Social, Patient Engagement
Interventions: A set of implementation strategies to reduce sexual stigma; Behavioral
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Herpes Zoster, Postherpetic Neuralgia
Interventions: Varicella-zoster vaccine, Placebo; Biological
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 60 Years and older
Enrollment: 38,456 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2011
U.S. locations: 22
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 19 more

Conditions: End Stage Renal Disease on Hemodialysis (Diagnosis)
Interventions: HEPLISAV-B®; Drug
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 20
States / cities: Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more

Conditions: Clostridium Difficile Infection (CDI)
Interventions: RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence); Drug
Lead sponsor: Rebiotix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 60
States / cities: Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Interferon beta-1b, Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Los Angeles, California • Orange, California • San Diego, California + 3 more

Conditions: Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
Interventions: HBIG, Epivir, Hepsera; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 13 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cytomegalovirus (CMV) Infections
Interventions: V160, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 2,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 54
States / cities: Birmingham, Alabama • Chandler, Arizona • Rialto, California + 41 more

Conditions: Surgical Wound Infection
Interventions: Aquacel Ag Surgical Dressing, Single-Use Negative Pressure Wound Therapy (PICO); Device
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pregnancy, Sexually Transmitted Infections
Interventions: Motivational Intervention, Didactic Educational Intervention; Behavioral
Lead sponsor: University of Rhode Island; Other
Eligibility: 14 Years to 21 Years · Female only
Enrollment: 272 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 5
States / cities: Cranston, Rhode Island • Exeter, Rhode Island • Providence, Rhode Island + 1 more

Conditions: HIV, AIDS, Substance Abuse, Inpatient
Interventions: Patient Navigation (PN) Group, Patient Navigator Plus Contingency Management (PN+CM) Group; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 801 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 12
States / cities: Birmingham, Alabama • Torrance, California • Miami, Florida + 8 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: Fisons; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza A Virus Infection
Interventions: H2N3 MO 2003/AA ca Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 42 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV Infections
Interventions: Truvada, Genvoya; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Frostbite
Interventions: Long-Acting silver dressings, Aloe Vera, Dalbavancin; Device · Other · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Home Parenteral Nutrition
Interventions: Caregiving support interventions (FamTechCare); Behavioral
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Human Immunodeficiency Virus Transmission, Sexually Transmitted Diseases
Interventions: HIV Prevention Decision Support Tool (DST), Standard Counseling; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 45 Years
Enrollment: 189 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Endophthalmitis, Cataract Surgery, Prophylaxis
Interventions: mupirocin ointment, SOC sterilization; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile, CDI
Interventions: VE303, Placebo; Drug
Lead sponsor: Vedanta Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 29
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more

Conditions: Hiv
Interventions: DOT mobile app; Other
Lead sponsor: Environment and Health Group, Inc.; Industry
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Search by objective public record fields.

SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults

HIV Oral Testing Infographic Experiment

Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA

Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus

Mitigating Sexual Stigma Within Healthcare Interactions Improve Engagement of MSM in HIV Prevention

Shingles Prevention Study

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Prevention of Recurrent Hepatitis B After Liver Transplantation

V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)

A Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO™) or Standard Care Dressings (AQUACEL® Ag SURGICAL Dressing)

Contraceptive Awareness and Reproductive Education

Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users

A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP

Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis

Technological Home Care: Improving HPN Care With Videophone And Internet Education

The OPENS Trial: Offering Women PrEP (Aim 1)

Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Mhealth for PrEP Adherence by Young Adult MSM, Phase 2